Immune Dysfunction in Allergic Asthma

This study has been completed.
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Mark Schuyler, University of New Mexico Identifier:
First received: September 10, 2005
Last updated: January 18, 2013
Last verified: January 2013
We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.

Condition Intervention
Drug: Xolair

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma

Resource links provided by NLM:

Further study details as provided by University of New Mexico:

Primary Outcome Measures:
  • anti-KLH antibody [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Asthma and control patients are immunized with KLH

Enrollment: 18
Study Start Date: September 2005
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: xolair
This is not a drug study examining differences of therapeutic outcomes. It uses Xolair as an intervention that might change the outcome of immunization.
Drug: Xolair
Patients are administered Xolair

Detailed Description:
Subjects with mild allergic asthma are examined before, immediately after and 2 months after a course of treatment with anti-IgE. The following are examined: Allergen skin tests, allergen induced asthma, peripheral blood basophils, pulmonary bronchial mucosal mast cells.

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Mild asthma, adults -

Exclusion Criteria:

children. on inhaled or systemic steroids

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00189228

United States, New Mexico
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
National Heart, Lung, and Blood Institute (NHLBI)
Study Director: Mark Schuyler, MD UNM HSC
  More Information

No publications provided

Responsible Party: Mark Schuyler, Professor of Medicine, University of New Mexico Identifier: NCT00189228     History of Changes
Obsolete Identifiers: NCT00201097
Other Study ID Numbers: UNMSCOR, R01HL044253
Study First Received: September 10, 2005
Last Updated: January 18, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases processed this record on November 30, 2015